BTK-IN-7

Cat. No.:	HY-143900
CAS No.:	2952702-39-3
Molecular Formula:	$C_{30}H_{32}N_6O_4$
Molecular Weight:	540.61
Target:	Btk; Apoptosis
Pathway:	Protein Tyrosine Kinase/RTK; Apoptosis
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description

BTK-IN-7 is a potent and selective inhibitor of BTK (IC_{50}=4.0 nM). BTK-IN-7 has high selectivity in both enzymatic (ITK >250-fold, EGFR >2500-fold) and cellular levels (ITK >227-fold, EGFR 27-fold). BTK-IN-7 also has potent antitumor activity[1].

In Vitro

BTK-IN-7 (compound 24a; 10, 100, 1000, 10000 nM; 48 hours) displays the antiproliferative effects in U-937 cells (IC_{50}=3.6 μM) [1].BTK-IN-7 (10, 100, 1000, 10000 nM; 48 hours; U937 cells) induces cell cycle arrest at the G1 phase in a concentration-dependent manner[1].BTK-IN-7 (1-5 μM; 48 hours) induces apoptosis in U-937 cells[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay[1]

Cell Line:	U937, Ramos, Pfeiffer, Jeko-1 cells
Concentration:	10, 100, 1000, 10000 nM
Incubation Time:	48 hours
Result:	Displayed antiproliferative effects in U-937 (IC_{50}=3.6 μM) cells.

Cell Cycle Analysis[1]

Cell Line:	U937 cells
Concentration:	10, 100, 1000, 10000 nM
Incubation Time:	48 hours
Result:	Cells were arrested atthe G1 phase in a concentration-dependent manner.

Apoptosis Analysis[1]

Cell Line:	U937 cells
Concentration:	1, 2.5, 5 μM
Incubation Time:	48 hours
Result:	An apoptosis rate was increased to 22.75% at a concentration of 5 μM.

In Vivo

BTK-IN-7 (25 and 50 mg/kg; intraperitoneal injection; daily for 14 days) inhibits tumor growth in a dose-dependent manner in U-937 xenograft mouse model, and 50 mg/kg dosage displays a better antitumor effect[1].
BTK-IN-7 does not shows significant parenchymal injury or inflammatory cell infiltration in organs[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male BALB/c nude mice (U397 xenograft mouse model) [1]
Dosage:	25, 50 mg/kg
Administration:	Intraperitoneal injection; daily for 14 days
Result:	Inhibited tumor growth in a dose-dependent manner and did not reveal significant parenchymal injury or inflammatory cell infiltration in organs.

REFERENCES

[1]. Dou D, et al. Discovery of Pteridine-7(8H)-one Derivatives as Potent and Selective Inhibitors of Bruton's Tyrosine Kinase (BTK). J Med Chem. 2022;65(3):2694-2709.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA